Abstract
Purpose
Despite numerous studies on the RRR- and all-rac-α-tocopherol isoform of vitamin E (VE) during aging, this relationship has not been examined in specific tissues. Since α-tocopherol is the most abundant of VE’s eight isoforms, and VE is an important antioxidant that impacts the aging process, we analyzed α-tocopherol levels in plasma and tissues of mice at progressive ages. Moreover, we examined protein and mRNA expression levels of hepatic α-tocopherol transfer protein (α-TTP), which specifically binds α-tocopherol, during aging.
Methods
The α-tocopherol levels in plasma, liver, cerebrum, hippocampus, cerebellum, heart, kidney, epididymal adipose tissue, testis, pancreas, soleus muscle, plantaris muscle, and duodenum from male C57BL/6NCr mice at 3, 6, 12, 18, and 24 months of age were determined by HPLC and fluorescence detection. Also, hepatic α-TTP protein and mRNA expression levels were analyzed by Western blot and qPCR, respectively.
Results
Tissue-specific, age-related changes of α-tocopherol levels normalized by tissue weight were observed in the liver, cerebrum, hippocampus, cerebellum, heart, kidney, and epididymal adipose tissue. Specifically, α-tocopherol levels in epididymal adipose tissue increased greatly as mice aged from 6 to 24 months. Although hepatic α-TTP protein levels also showed age-related changes, α-TTP mRNA expression levels measured after overnight fasting were not altered.
Conclusions
In this study, we determined that α-tocopherol levels and hepatic α-TTP protein levels of mice undergo significant tissue-specific, age-related changes. This is the first report to investigate VE in terms of the α-tocopherol levels in plasma and various tissues of mice and hepatic α-TTP protein levels during aging.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Vitamin E (VE) is a lipid-soluble antioxidant that localizes mainly at cell membranes [1]. VE consists of eight isoforms: α-, β-, γ-, and δ-tocopherol and α-, β-, γ-, and δ-tocotrienol. In animals, dietary VE is absorbed from the small intestine accompanied by other lipophilic nutrients and integrated into chylomicrons [2]. Chylomicrons containing VE eventually reach the liver, where they are incorporated by endocytosis into hepatocytes. Then, only the α-tocopherol component is selectively secreted from the liver with the help of α-tocopherol transfer protein (α-TTP). In hepatocytes, α-TTP selectively binds α-tocopherol and moves to the cell membrane [3]. Afterward, α-tocopherol is transported into plasma lipoproteins by ATP-binding cassettes, subfamily A, member 1 (ABCA1), and then distributed to peripheral tissues [4, 5]. Consequently, α-tocopherol becomes most abundant in peripheral tissues.
α-TTP is a member of the Sec14 superfamily and also binds phosphatidylinositol bisphosphate (PIP2) [6]. When α-TTP moves to cells’ membranes with α-tocopherol, α-tocopherol is exchanged with PIP2 on the cell membrane accompanying conformational changes of the α-TTP protein. Impaired α-TTP caused by genetic mutation in the binding domain of α-tocopherol or PIP2 is responsible for ataxia by VE deficiency [7]. Therefore, α-TTP functions to systematically maintain the α-tocopherol level in peripheral tissues.
Reactive oxygen species are known to oxidize DNA, protein, and lipids and are thought to be one cause of aging [8]. Hydroxyl radicals, which are members of the reactive oxygen species, oxidize polyunsaturated fatty acids and produce lipid peroxyl radicals. In turn, lipid peroxyl radicals react with another fatty acid to produce lipid peroxide [9]. Since VE, as an antioxidant, has the ability to reduce lipid peroxide content and to eliminate lipid peroxyl radicals [1], many investigators have attempted to clarify the relationships between blood VE level and age-associated disease. For example, serum VE levels were lower in the sera of patients with age-related macular degeneration than that of age-matched, normal controls [10].
Frequently, hospitalized elderly patients have reduced plasma α-tocopherol levels [11]. Additionally, aged persons with even mild cognitive impairments or the more debilitating neurodegenerative disorders such as senile dementia or Alzheimer’s disease have low α-tocopherol levels in plasma [12, 13]. Moreover, large doses of VE supplementation have prolonged the life spans of mice [14], although others reported, conversely, that substantial VE supplementation lacked any effect on the duration of life [15]. Thus, whether VE has the power to affect longevity is still unclear, as reviewed by Ernst et al. [16].
Since VE levels have not been measured in multiple tissues during aging, this study was performed to determine the VE level by calculating α-tocopherol levels in plasma, liver, cerebrum, hippocampus, cerebellum, heart, kidney, epididymal adipose tissue, testis, pancreas, soleus muscle, plantaris muscle, and duodenum of mice during aging. Simultaneously, we investigated the hepatic α-TTP protein and mRNA expression levels during aging, because their levels affect VE levels in plasma and tissues. Our results demonstrated that marked tissue-specific, age-related changes of α-tocopherol and hepatic α-TTP protein levels occur in mice as they advance in age.
Materials and methods
Animals
Male mice of the C57BL/6NCr strain were obtained at 3, 6, 12, 18, and 24 months of age from the animal facility at Tokyo Metropolitan Institute of Gerontology (Tokyo, Japan). All mice were fed a CRF-1 solid diet (Oriental Yeast, Tokyo, Japan), which contained 20.1 mg VE (α-tocopherol: 16.5 mg, β-tocopherol: 0.6 mg, γ-tocopherol: 2.5 mg, δ-tocopherol: 0.5 mg) per 100 g. After overnight fasting (18 h), mice were killed, and blood was collected from the right atrium. Blood was gently mixed with ethylenediaminetetraacetic acid (EDTA) and centrifuged at 880 g for 15 min at 4 °C. The resulting supernatants were used as plasma for further analysis. Afterward, mice were perfused systemically with ice-cold phosphate-buffered saline through the left ventricle to wash out the remaining blood cells. Liver, cerebrum, hippocampus, cerebellum, heart, kidney, epididymal adipose tissue, testis, pancreas, soleus muscle, plantaris muscle, and duodenum were collected and stored at −80 °C until use. All experimental procedures using laboratory animals were approved by the Animal Care and Use Committee of Tokyo Metropolitan Institute of Gerontology.
Determination of α-tocopherol in plasma and tissues
Liver, cerebrum, hippocampus, cerebellum, epididymal adipose tissue, testis, and pancreas were homogenized with a teflon pestle homogenizer in phosphate-buffered saline. Heart, kidney, soleus muscle, plantaris muscle, and duodenum were crushed with Cryo-Press (Microtech, Chiba, Japan) and suspended in phosphate-buffered saline. The homogenates and plasma were mixed with 5 % ascorbic acid, 70 % ethanol, and dl-tocol (Tama Biochemical Co., Ltd., Tokyo, Japan). The mixture was incubated with n-hexane and centrifuged at 21,000 g. The upper n-hexane layer, which contained α-tocopherol and dl-tocol, was removed. Hexane was evaporated and the residue was redissolved in ethanol. Both α-tocopherol and dl-tocol content were determined by using high-performance liquid chromatography (HPLC) (Waters 2695 separations module, Nihon Waters, Tokyo, Japan) and a fluorescence detector (Waters 2475 Multi λ fluorescence detector, Nihon Waters) (Supplementary Figure S1). Separation was achieved on a cadenza CD-C18 column (3 µm, 4.6 × 150 mm, Imtakt Corporation, Kyoto, Japan) combined with a cadenza CD-C18 guard column (3 µm, 2.0 × 5.0 mm, Imtakt Corporation). The mobile phase was 90 % ethanol, and flow rate was 0.7 mL/min. Temperatures for the column and autosampler were set at 40 and 4 °C, respectively. Fifteen µL of each sample was injected into the HPLC and fluorescence detector system. Both α-tocopherol and dl-tocol were detected by excitation wavelength at 298 nm and emission wavelength at 325 nm (Supplementary Figure S1). The level of α-tocopherol was normalized by dl-tocol as an internal standard and determined from serial-diluted RRR-α-tocopherol standard (Tama Biochemical Co., Ltd.) curve (Supplementary Figure S1).
Determination of triglyceride (TG)
Total lipid was extracted by the Folch method [17] as described previously [18]. Tissues were homogenized with a teflon pestle homogenizer in ultrapure water, and homogenates were incubated with chloroform–methanol (2:1) at 37 °C for 1 h. After incubation, samples were centrifuged at 21,000 g, and precipitates were washed with chloroform–methanol (2:1) at 37 °C for 2 h. Total lipid was obtained by evaporating the supernatant to dryness at 55 °C in N2 gas and dissolution in 2-propanol. TG content was determined by using enzymatic assay kits (Wako Pure Chemical, Osaka, Japan).
Western blot analysis of α-TTP
Livers were homogenized with buffer containing 25 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1 % IGEPAL® CA-630 (Sigma-Aldrich, Tokyo, Japan), 1 % sodium deoxycholate, 0.1 % SDS, complete EDTA-free protease inhibitor cocktail (Roche Diagnostics, Tokyo, Japan) using a polytron homogenizer. Protein concentrations were measured by the Lowry method [19]. Each sample (10 µg protein) was electrophoresed on 12 % polyacrylamide gel by the method of Laemmli [20] with some modifications. After electrophoresis, proteins were transferred onto polyvinylidene fluoride membranes (Immobilon®-FL, Merck Millipore, Billerica, MA, USA). The primary antibodies used were rat anti-α-TTP monoclonal antibody (A8-F1) (1:2000) generated as described previously [21] and rabbit anti-β-actin polyclonal antibody (1:1000) purchased from Santa Cruz Biotechnology (Texas, USA). The secondary antibodies were IRDye 680RD goat anti-rat IgG (1:15,000) and IRDye 800CW goat anti-rabbit IgG (1:15,000) purchased from LI-COR Biosciences (Lincoln, NE, USA). Secondary antibodies were detected as fluorescence with the Odyssey® CLx Infrared Imaging System (LI-COR Biosciences, Lincoln, NE, USA). Densitometric analyses were performed by Image Studio, version 2.1.10 (LI-COR Biosciences). Protein levels of α-TTP were evaluated relative to the β-actin levels and expressed as ratios when compared to 3-month-old mice.
Extraction of total RNA and cDNA synthesis
Total RNA was extracted by using ISOGEN® (Wako Pure Chemical) [22]. Tissues were homogenized with a teflon pestle homogenizer and polytron homogenizer in ISOGEN, and total RNA was extracted according to the manufacturer’s protocol. The final RNA pellet was dissolved in RNase-free sterile water. RNA concentrations were determined by measuring absorbance at 260 nm and confirmed as free from protein contamination by measuring absorbance ratios of 260 and 280 nm. Then, cDNA was synthesized using SuperScript III Reverse transcriptase (Invitrogen) following the manufacturer’s protocol. The cDNA was stored at −80 °C until use.
Quantitative polymerase chain reaction (qPCR)
Using the qPCR super mix-UDG-with ROX (Invitrogen), qPCR was performed following the manufacturer’s protocol. The primers and 5′-carboxyfluorescein (6-FAM)/N,N-diethyl-4-(4-nitronaphthalen-1-ylazo)-phenylamine (ZEN)/Iowa Black® FQ-3′ double quenched probes of α-TTP, cytochrome P450, family 4, subfamily f, polypeptide 14 (Cyp4f14), ABCA1, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and β-actin were purchased from Integrated DNA Technologies, Inc. (Coralville, IA, USA) [23]. The reactions were performed by using the real-time PCR equipment (StepOne Plus, Applied Biosystems, Foster City, CA, USA). The amplification protocol consisted of denaturation at 95 °C for 2 min, 45 cycles of 95 °C for 15 s, and 60 °C for 30 s. For quantitative analysis of each mRNA expression level, a standard curve method was designed; that is, an aliquot from each experimental sample was used to generate standard curves. The α-TTP, Cyp4f14, and ABCA1 mRNA expression levels in liver from mice of various ages were expressed as the ratio when compared to 3-month-old mice. The α-TTP mRNA expression levels in various tissues were expressed as the ratio when compared to livers from 12-month-old mice.
Fasting study
Male mice of C57BL/6NCr strain at 3 months of age were fasted for 3 and 18 h. After fasting, mice were killed and perfused systemically with ice-cold phosphate-buffered saline through the left ventricle to wash out the remaining blood cells. Livers were collected and stored at −80 °C until use. We used non-fasted mice as controls.
Statistical analysis
Results were expressed as mean ± standard error of the mean (SEM). The probability of statistical differences between each experimental groups was determined by one-way analysis of variance (ANOVA) followed by Tukey’s test using GraphPad Prism 6 (GraphPad Software Inc., San Diego, CA, USA). Statistical differences were considered significant at P < 0.05.
Results
Body and tissue weights of mice at progressive ages
Mean body and individual tissue weights of mice at 3, 6, 12, 18, and 24 months of age are shown in Table 1. Mean whole body weights increased from 3 to 12 months of age and then decreased until 24 months of age. Mean liver and heart weights increased from the 3 to 24 months of age. Mean kidney weights increased from 3 to 18 months of age, and epididymal adipose tissue weights increased from 3 to 12 months of age and then decreased until 24 months of age. Mean testis weights increased from 3 to 6 months and then decreased until 24 months of age. Mean pancreas weights increased from 12 to 18 months of age and then decreased at 24 months of age. No such differences were observed in the mean brain weights at progressive ages.
Age-related change of α-tocopherol levels in plasma and various tissues normalized by tissue weight
To investigate the age-related change of α-tocopherol levels, we examined plasma, liver, cerebrum, hippocampus, cerebellum, heart, kidney, epididymal adipose tissue, testis, pancreas, soleus muscle, plantaris muscle, and duodenum of mice at 3, 6, 12, 18, and 24 months of age. Values for each of those tissues were normalized with tissue weight excluding plasma (Fig. 1). In the liver and heart, α-tocopherol levels increased from 3 to 6 months of age and then decreased from 6 to 24 months (Fig. 1b, f). The α-tocopherol levels in the liver and heart of mice at 24 months of age were 45 and 27 % lower than those of mice at 6 months of age, respectively. On the other hand, α-tocopherol levels in the cerebrum and hippocampus increased from 3 to 12 months of age (Fig. 1c, d). The α-tocopherol levels in the cerebrum and hippocampus of mice at 12 months of age were 85 and 89 % higher than that of mice at 3 months of age, respectively. In the cerebellum, α-tocopherol increased slightly from 3 to 18 months of age until becoming 30 % higher at the 18 month mark than that at 3 months of age (Fig. 1e). Notably the kidney contained 43 % more α-tocopherol in 24-month-old mice than those at 3 months of age (Fig. 1g), but no significant difference was observed between 18 and 24 months of age. In epididymal adipose tissue, the amount of α-tocopherol rose dramatically from 6 to 24 months of the animals’ ages to a final 25-fold higher content (Fig. 1h). There were no significant differences of α-tocopherol levels in plasma, which were not normalized with tissue weight, testis, pancreas, soleus muscle, plantaris muscle, or duodenum during aging (Fig. 1a, i–m).
Age-related change of α-tocopherol levels normalized with TG
Since α-tocopherol is a lipid-soluble antioxidant, α-tocopherol levels in tissues might be influenced by their lipid content. Therefore, we used enzymatic assays to assess TG in plasma, liver, and epididymal adipose tissue of mice at 3, 6, 12, 18, and 24 months of age, and α-tocopherol levels were normalized with TG (Fig. 2). In the liver, TG content increased profoundly from 3 to 6 months of age and then decreased from 6 to 24 months of age (Fig. 2b). That is, 6-month-old mice had 229 % more liver TG than the 3-month-olds, and those at 24 months of age had 43 % less liver TG than the 6-month-olds. In epididymal tissue, TG content appeared to increase from 18 to 24 months of age, but the difference was not statistically significant (Fig. 2c). In plasma, TG content did not change during aging (Fig. 2a).
We then normalized α-tocopherol levels with TG in plasma, liver, and epididymal adipose tissues (Fig. 2d–f). In the liver, α-tocopherol levels decreased greatly from 3 to 6 months of age (the latter was 65 % lower) and then remained almost stable from 6 to 24 months of age (Fig. 2e). Again, epididymal adipose tissue gained a notable 18-fold increase of α-tocopherol by the time mice aged from 6 to 24 months (Fig. 2f). There was no significant difference of α-tocopherol level in plasma during aging (Fig. 2d).
Age-related changes of α-TTP protein and mRNA expression levels in liver
We next examined α-TTP protein and mRNA expression levels in the liver, because α-TTP is a major determinant of α-tocopherol levels of plasma and tissues [24]. As shown in Fig. 3, α-TTP protein levels increased from 3 to 12 months of age and then decreased until 24 months of age. Protein levels of α-TTP in livers of mice at 12 months of age were 122 and 161 % higher than that of mice at 3 and 24 months of age, respectively (Fig. 3b). However, there was no significant difference in α-TTP mRNA expression level in the liver during aging (Fig. 4a).
α-TTP mRNA expression in various tissues
To confirm the α-TTP mRNA expression levels in various tissues, we performed qPCR analysis. All tissues examined contained α-TTP mRNA, i.e., cerebrum, hippocampus, cerebellum, heart, kidney, epididymal adipose tissue, testis, pancreas, soleus muscle, plantaris muscle, and duodenum, although the levels in these tissues were much lower than that in the liver (Fig. 4b).
Age-related changes of Cyp4f14 and ABCA1 mRNA expression levels in the liver
As well-documented, α-tocopherol is transported to the plasma membrane by α-TTP in liver cells, transferred to plasma lipoproteins such as very low density lipoprotein (VLDL) by ABCA1, and then distributed to peripheral tissues [4, 5]. Moreover, α-tocopherol is catabolized by Cyp4f14 in mouse livers [25, 26]. Thus, hepatic Cyp4f14 and ABCA1 are also key factors for determining α-tocopherol levels in plasma and tissues [27]. Therefore, we examined Cyp4f14 and ABCA1 mRNA expression in livers of mice at 3, 6, 12, 18, and 24 months of age (Fig. 4c, d). Cyp4f14 mRNA expression decreased from 3 to 6 months of age, increased from 6 to 12 months of age, then gradually decreased for the next 12–24 months (Fig. 4c). Cyp4f14 mRNA expression was 30 % lower in the liver at 6 months than at 3 months of age and, by 24 months of age, was 49 % lower than that at 12 months of age. On the other hand, ABCA1 mRNA expression increased from 3 to 6 months of age and then remained at almost the same levels during 6–24 months of age (Fig. 4d). ABCA1 mRNA expression levels in the livers of 6-month-old mice was 30 % higher than that at 3 months of age.
Effect of fasting on α-TTP, Cyp4f14, and ABCA1 mRNA expression levels in liver
To elucidate the effect of fasting on the α-TTP, Cyp4f14, and ABCA1 mRNA, we examined these mRNA expression levels in livers from 3- to 18-h-fasted mice and non-fasted, matched controls. The α-TTP mRNA expression levels in livers from 18-h-fasted mice were 1.8-fold higher than that from 3-h-fasted and non-fasted mice (Fig. 5a). However, no significant difference was evident in α-TTP mRNA expression levels between 3-h-fasted and non-fasted mice. Cyp4f14 mRNA expression in livers from 18-h-fasted mice was 30 % lower than in 3-h-fasted mice and non-fasted mice (Fig. 5b), whereas the 3-h-fast and non-fasted state produced no significant difference in Cyp4f14 mRNA expression. The ABCA1 mRNA expression levels in livers from 18-h-fasted mice were 1.3-fold higher than that from 3-h-fasted mice (Fig. 5c). However, there was no significant difference of ABCA1 mRNA expression between mice fasted for 3 or 18-h and non-fasted mice.
Discussion
In the years-long debate about the efficacy of VE as an antioxidant that benefits human health, this is the first report to verify the content of α-tocopherol, a major component of VE, in plasma and key tissues of mice during aging. We documented significant differences during aging, most notably in the liver and epididymal adipose tissue. Moreover, hepatic α-TTP protein levels showed age-related changes.
In this study, we first clarified the α-tocopherol levels in plasma and 12 tissues of male mice as they advanced from 3 to 24 months of age. We also examined TG content in plasma, liver, and epididymal adipose tissue of mice during aging and normalized α-tocopherol levels by TG, because α-tocopherol is a lipid-soluble antioxidant and α-tocopherol level in tissues might be influenced by the amount of lipid. Interestingly, the hepatic TG content increased dramatically from 3 to 6 months of age; in contrast, hepatic α-tocopherol levels normalized with TG decreased from 3 to 6 months of age. These results indicate that hepatic α-tocopherol level is not directly proportional to the hepatic TG contents during aging. Moreover, the hepatic α-tocopherol level normalized according to tissue weight decreased during the period from 6 to 24 months, but no such differences occurred in hepatic α-tocopherol level normalized with TG for the same 6–24 month span. Thus, age-related changes of hepatic α-tocopherol levels varied depending on the normalization agent.
We found that hepatic α-TTP protein levels increased from 3 to 12 months of age and then decreased until 24 months of age, although age-related changes of hepatic α-tocopherol levels did coincide with hepatic α-TTP protein levels, which were normalized with tissue weight or TG. Since α-TTP is responsible for releasing α-tocopherol from the liver [27], reduction of hepatic α-TTP protein levels late in life (in mice from 12 to 24 months of age) might result in the accumulation of hepatic α-tocopherol. However, hepatic α-tocopherol levels decreased when normalized to tissue weight or maintained almost same levels when normalized to TG from 12 to 24 months. This discrepancy suggests that hepatic α-tocopherol content must be controlled not only by hepatic α-TTP protein but also other factors that may participate in the transport and/or metabolism of α-tocopherol in the liver. As mentioned earlier, ABCA1, which secrets α-tocopherol out of liver cells, and Cyp4f14 that oxidatively catabolizes α-tocopherol are possible candidates to control the hepatic α-tocopherol level as well as α-TTP. We examined Cyp4f14 and ABCA1 mRNA expression in livers of mice during aging and found that Cyp4f14 mRNA expression levels decreased from 12 to 24 months of age, yet ABCA1 remained at almost static from 6 to 24 months of age. Thus, age-related changes of ABCA1 mRNA expression levels in the liver were coincident with hepatic α-tocopherol levels normalized with TG. However, age-related changes of Cyp4f14 mRNA expression levels in the liver did not correlate with hepatic α-tocopherol levels normalized with both tissue weight and TG, because reductions in Cyp4F14 should promote the accumulation of α-tocopherol in the liver at progressive ages. Grebenstein et al. [28] reported that hepatic α-tocopherol levels reduced in α-TTP knockout mice and sesamin which is a Cyp4F14 inhibitor did not affect the α-tocopherol catabolism. Accordingly, age-related changes of hepatic α-tocopherol levels may not be due to the α-tocopherol catabolism involved in Cyp4F14.
Hepatic α-TTP protein levels showed age-related changes; however, there were no significant differences of α-TTP mRNA expression levels in the liver during aging. To account for this discrepancy, we examined the effect of fasting on the α-TTP mRNA expression. In mice fasted to avoid the influence of food intake, we noted that α-TTP mRNA expression in the liver from 18-h-fasted mice was 1.8-fold higher than that from 3-h-fasted and non-fasted mice. Thus, fasting clearly increased α-TTP mRNA expression. Thakur et al. [29] reported that intracellular α-tocopherol inhibited α-TTP protein degradation of HepG2-TetOn-α-TTP cells, which stably expressed HA-tagged α-TTP protein under the inducible TetOn promoter. Therefore, α-TTP protein stability is presumably influenced by intracellular α-tocopherol levels at progressive ages, thereby providing a possible reason for the discrepancy in age-related changes between α-TTP protein and mRNA expression. On the other hand, Cyp4f14 mRNA expression levels decreased from 12 to 24 months of age and also decreased after 18 h of fasting. The catabolic pathway of α-tocopherol might be suppressed to avoid the reduction of hepatic α-tocopherol levels and also to avoid a reduction of α-tocopherol levels in the liver at progressive ages. Moreover, ABCA1 mRNA expression remained at virtually the same level throughout 6–24 months of aging and increased slightly after 18 h of fasting when compared to the 3-h-fasting; however, there was no significant difference in ABCA1 mRNA expression levels between both 3- and 18-h-fasted and non-fasted mice. Consequently, ABCA1 might be expressed constitutively to maintain lipid metabolism and hardly be influenced by α-tocopherol levels and aging.
In this study, epididymal adipose tissue weights increased from 3 to 12 months of age and then decreased until 24 months of age. These age-related changes of epididymal adipose tissue weights were in good agreement with previous reports [30, 31]. This phenomenon must be due to reduced differentiation capacity of preadipocytes and fat deposit during aging caused by decreased adipogenic transcription factor such as CCAAT/enhancer binding protein α (C/EBPα) and peroxisome proliferator-activated receptor γ (PPARγ), and increased anti-adipogenic regulators such as tumor necrosis factor α (TNFα) as reviewed by Kirkland et al. [32].
Moreover, in epididymal adipose tissue, α-tocopherol levels increased from 6 to 24 months of age irrespective of normalization. Interestingly, α-tocopherol levels normalized with tissue weight and TG at 24 months of age were 25- and 18-fold higher than that at 6 months of age, respectively. On the other hand, TG contents in epididymal tissue increased only slightly from 18 to 24 months of age, strongly suggesting that aged animals must accumulate high concentrations of α-tocopherol in the epididymis. If so, high concentrations of α-tocopherol may play an important role in preventing the oxidation of stored lipids. Furthermore, epidermal tissue may be the place to store α-tocopherol and to release it for maintenance of physiological functions in the brain. Also, specific machinery may exist to incorporate and accumulate α-tocopherol into adipose tissue. Further analyses are needed to clarify that hypothesis.
In the case of plasma, no significant differences were apparent in α-tocopherol levels during aging even when α-tocopherol levels were normalized with TG. Plasma α-tocopherol might be strictly controlled at constant levels during aging.
Fukui et al. [33] reported that α-tocopherol-deficient rats displayed cognitive dysfunction. Others noted that α-tocopherol was essential for Purkinje neuron integrity and prevented high-fat, high-carbohydrate diet-induced memory impairment [34, 35]. In the present study, α-tocopherol levels in the cerebrum, hippocampus, and cerebrum normalized with tissue weight increased for animals from 3 to 18 months of age and maintained α-tocopherol levels at those progressive ages. Therefore, α-tocopherol may be essential to prevent memory impairment and to maintain neuronal cells during aging.
To summarize, α-tocopherol levels in the liver showed significant differences during aging when normalized with tissue weights. Moreover, hepatic α-TTP protein levels underwent age-related changes, although α-TTP mRNA expression measured after overnight fasting was not altered during aging. Interestingly, the α-tocopherol level in epididymal adipose tissue, when normalized with tissue weight and with TG, increased profoundly from 6 to 24 months of age; however, no such age-related changes were observed in plasma. This detailed investigation of bodily changes in content of the VE component, α-tocopherol, during the aging process provides a new foundation for pursuing the usefulness of VE supplementation to human health.
Abbreviations
- ABCA1:
-
ATP-binding cassette subfamily A, member 1
- ANOVA:
-
One-way analysis of variance
- C/EBPα:
-
CCAAT/enhancer binding protein α
- Cyp4f14:
-
Cytochrome P450, family 4, subfamily f, polypeptide 14
- EDTA:
-
Ethylenediaminetetraacetic acid
- 6-FAM:
-
5′-carboxyfluorescein
- GAPDH:
-
Glyceraldehyde 3-phosphate dehydrogenase
- HPLC:
-
High-performance liquid chromatography
- qPCR:
-
Quantitative polymerase chain reaction
- PIP2 :
-
Phosphatidylinositol bisphosphate
- PPARγ:
-
Peroxisome proliferator-activated receptor γ
- SEM:
-
Standard error of the mean
- TG:
-
Triglyceride
- TNFα:
-
Tumor necrosis factor α
- α-TTP:
-
Alpha tocopherol transfer protein
- VE:
-
Vitamin E
- VLDL:
-
Very low density lipoprotein
- ZEN:
-
N,N-diethyl-4-(4-nitronaphthalen-1-ylazo)-phenylamine
References
Niki E (2014) Role of vitamin E as a lipid-soluble peroxyl radical scavenger: in vitro and in vivo evidence. Free Radic Biol Med 66:3–12
Traber MG, Burton GW, Ingold KU, Kayden HJ (1990) RRR- and SRR-α-tocopherols are secreted without discrimination in human chylomicrons, but RRR-α-tocopherol is preferentially secreted in very low density lipoproteins. J Lipid Res 31:675–685
Hosomi A, Arita M, Sato Y, Kiyose C, Ueda T, Igarashi O, Arai H, Inoue K (1997) Affinity for α-tocopherol transfer protein as a determinant of the biological activities of vitamin E analogs. FEBS Lett 409:105–108
Shichiri M, Takanezawa Y, Rotzoll DE, Yoshida Y, Kokubu T, Ueda K, Tamai H, Arai H (2010) ATP-binding cassette transporter A1 is involved in hepatic α-tocopherol secretion. J Nutr Biochem 21:451–456
Christiansen-Weber TA, Voland JR, Wu Y, Ngo K, Roland BL, Nguyen S, Peterson PA, Fung-Leung WP (2000) Functional loss of ABCA1 in mice causes severe placental malformation, aberrant lipid distribution, and kidney glomerulonephritis as well as high-density lipoprotein cholesterol deficiency. Am J Pathol 157:1017–1029
Bankaitis VA, Mousley CJ, Schaaf G (2010) The Sec14 superfamily and mechanisms for crosstalk between lipid metabolism and lipid signaling. Trends Biochem Sci 35:150–160
Kono N, Ohto U, Hiramatsu T, Urabe M, Uchida Y, Satow Y, Arai H (2013) Impaired α-TTP-PIPs interaction underlies familial vitamin E deficiency. Science 340:1106–1110
Radak Z, Zhao Z, Goto S, Koltai E (2011) Age-associated neurodegeneration and oxidative damage to lipids, proteins and DNA. Mol Asp Med 32:305–315
Winterbourn CC (2008) Reconciling the chemistry and biology of reactive oxygen species. Nat Chem Biol 4:278–286
Belda JI, Roma J, Vilela C, Puertas FJ, Diaz-Llopis M, Bosch-Morell F, Romero FJ (1999) Serum vitamin E levels negatively correlate with severity of age-related macular degeneration. Mech Ageing Dev 107:159–164
Tébi A, Belbraouet S, Chau N, Debry G (2000) Plasma vitamin, β-carotene, and α-tocopherol status according to age and disease in hospitalized elderly. Nutr Res 20:1395–1408
Cherubini A, Martin A, Andres-Lacueva C, Di Iorio A, Lamponi M, Mecocci P, Bartali B, Corsi A, Senin U, Ferrucci L (2005) Vitamin E levels, cognitive impairment and dementia in older persons: the InCHIANTI study. Neurobiol Aging 26:987–994
Mangialasche F, Xu W, Kivipelto M, Costanzi E, Ercolani S, Pigliautile M, Cecchetti R, Baglioni M, Simmons A, Soininen H, Tsolaki M, Kloszewska I, Vellas B, Lovestone S, Mecocci P (2012) Tocopherols and tocotrienols plasma levels are associated with cognitive impairment. Neurobiol Aging 33:2282–2290
Navarro A, Gomez C, Sanchez-Pino MJ, Gonzalez H, Bandez MJ, Boveris AD, Boveris A (2005) Vitamin E at high doses improves survival, neurological performance, and brain mitochondrial function in aging male mice. Am J Physiol Regul Integr Comp Physiol 289:R1392–R1399
Morley AA, Trainor KJ (2001) Lack of an effect of vitamin E on lifespan of mice. Biogerontology 2:109–112
Ernst IM, Pallauf K, Bendall JK, Paulsen L, Nikolai S, Huebbe P, Roeder T, Rimbach G (2013) Vitamin E supplementation and lifespan in model organisms. Ageing Res Rev 12:365–375
Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226:497–509
Takahashi K, Kishimoto Y, Konishi T, Fujita Y, Ito M, Shimokado K, Maruyama N, Ishigami A (2014) Ascorbic acid deficiency affects genes for oxidation-reduction and lipid metabolism in livers from SMP30/GNL knockout mice. Biochim Biophys Acta 1840:2289–2298
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275
Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685
Kaempf-Rotzoll DE, Igarashi K, Aoki J, Jishage K, Suzuki H, Tamai H, Linderkamp O, Arai H (2002) α-tocopherol transfer protein is specifically localized at the implantation site of pregnant mouse uterus. Biol Reprod 67:599–604
Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156–159
Lennox KA, Owczarzy R, Thomas DM, Walder JA, Behlke MA (2013) Improved performance of anti-miRNA oligonucleotides using a novel non-nucleotide modifier. Mol Ther Nucleic Acids 2:e117
Kaempf-Rotzoll DE, Traber MG, Arai H (2003) Vitamin E and transfer proteins. Curr Opin Lipidol 14:249–254
Parker RS, Sontag TJ, Swanson JE, McCormick CC (2004) Discovery, characterization, and significance of the cytochrome P450 ω-hydroxylase pathway of vitamin E catabolism. Ann N Y Acad Sci 1031:13–21
Bardowell SA, Ding X, Parker RS (2012) Disruption of P450-mediated vitamin E hydroxylase activities alters vitamin E status in tocopherol supplemented mice and reveals extra-hepatic vitamin E metabolism. J Lipid Res 53:2667–2676
Traber MG (2013) Mechanisms for the prevention of vitamin E excess. J Lipid Res 54:2295–2306
Grebenstein N, Schumacher M, Graeve L, Frank J (2014) α-Tocopherol transfer protein is not required for the discrimination against gamma-tocopherol in vivo but protects it from side-chain degradation in vitro. Mol Nutr Food Res 58:1052–1060
Thakur V, Morley S, Manor D (2010) Hepatic α-tocopherol transfer protein: ligand-induced protection from proteasomal degradation. Biochemistry 49:9339–9344
Donato AJ, Henson GD, Hart CR, Layec G, Trinity JD, Bramwell RC, Enz RA, Morgan RG, Reihl KD, Hazra S, Walker AE, Richardson RS, Lesniewski LA (2014) The impact of ageing on adipose structure, function and vasculature in the B6D2F1 mouse: evidence of significant multisystem dysfunction. J Physiol 592:4083–4096
Tchkonia T, Morbeck DE, Von Zglinicki T, Van Deursen J, Lustgarten J, Scrable H, Khosla S, Jensen MD, Kirkland JL (2010) Fat tissue, aging, and cellular senescence. Aging Cell 9:667–684
Kirkland JL, Tchkonia T, Pirtskhalava T, Han J, Karagiannides I (2002) Adipogenesis and aging: does aging make fat go MAD? Exp Gerontol 37:757–767
Fukui K, Omoi NO, Hayasaka T, Shinnkai T, Suzuki S, Abe K, Urano S (2002) Cognitive impairment of rats caused by oxidative stress and aging, and its prevention by vitamin E. Ann N Y Acad Sci 959:275–284
Ulatowski L, Parker R, Warrier G, Sultana R, Butterfield DA, Manor D (2014) Vitamin E is essential for Purkinje neuron integrity. Neuroscience 260:120–129
Alzoubi KH, Khabour OF, Salah HA, Hasan Z (2013) Vitamin E prevents high-fat high-carbohydrates diet-induced memory impairment: the role of oxidative stress. Physiol Behav 119:72–78
Acknowledgments
We are grateful to Mr. H. Tamura, Eisai Food and Chemical Co., Ltd. Japan, for providing dl-tocol and α-tocopherol standards. We also thank Dr. K. Fukui, Shibaura Institute of Technology for technical assistance and Ms. P. Minick for the excellent English editorial assistance. This study is supported by Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number 24380073 (A.I.).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Takahashi, K., Takisawa, S., Shimokado, K. et al. Age-related changes of vitamin E: α-tocopherol levels in plasma and various tissues of mice and hepatic α-tocopherol transfer protein. Eur J Nutr 56, 1317–1327 (2017). https://doi.org/10.1007/s00394-016-1182-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00394-016-1182-4